PVLA · CIK 0001583648 · operating
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing topical therapies for rare genetic skin diseases. The company's primary focus is QTORIN, a 3.9% rapamycin anhydrous gel formulation currently in Phase 3 clinical trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations. QTORIN targets mTOR-driven skin conditions, with the company exploring additional indications beyond its lead indication.
As a pre-revenue clinical-stage entity, Palvella has not yet established commercial product revenue streams. The company operates with a lean organizational structure of 14 full-time employees and is headquartered in Wayne, Pennsylvania. The company is listed on Nasdaq, with a market capitalization of $1.8 billion as of the available data date.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-7.83 | $-7.83 | -2800.0% | |
| 2023 | — | $-0.27 | +40.0% | |
| 2022 | — | $-0.45 | +36.6% | |
| 2021 | $-0.71 | $-0.71 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-31 | 0000950170-25-047212 | SEC ↗ |
| 2023-12-31 | 2024-03-29 | 0001437749-24-010123 | SEC ↗ |
| 2022-12-31 | 2023-03-31 | 0001437749-23-008834 | SEC ↗ |
| 2021-12-31 | 2022-03-02 | 0001583648-22-000016 | SEC ↗ |
| 2020-12-31 | 2021-03-31 | 0001583648-21-000005 | SEC ↗ |
| 2019-12-31 | 2020-03-13 | 0001583648-20-000015 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001583648-19-000011 | SEC ↗ |
| 2017-12-31 | 2018-03-15 | 0001583648-18-000017 | SEC ↗ |
| 2016-12-31 | 2017-03-30 | 0001193125-17-102052 | SEC ↗ |
| 2015-12-31 | 2016-03-23 | 0001193125-16-514870 | SEC ↗ |
| 2014-12-31 | 2015-03-30 | 0001193125-15-109883 | SEC ↗ |
| 2014-06-30 | 2014-09-12 | 0001583648-14-000010 | SEC ↗ |